↑
Stewardship principles
Sustainable business practices Continuously held since: 2016 Holding as at end 2025: 10.72 percent
Continuously held since: 2016 Holding as at end 2025: 10.72 percent
Ambu is a Danish medtech company and a pioneer in the development of single-use endoscopes. These are thin, flexible, sterile tubes with a light and a camera that allow clinicians to see inside the body. These tools are used across multiple medical specialities, reducing the risk of infection, avoiding complex reprocessing and enhancing the reliability of critical healthcare services. We believe that Ambu is well positioned to drive the industry-wide shift from reusable to single-use endoscopes and deliver long-term growth.
| Engagement type | First engaged on the topic | |
|---|---|---|
| Encourage Ambu to continue developing its sustainability strategy to support future growth. | Influencing | 2022 |
| Support disciplined growth in emerging markets | Influencing | 2023 |
Status
Ongoing
Ongoing
Single-use endoscopes are well-suited to healthcare systems in emerging markets due to lower infrastructure requirements and improved reliability. However, a key determinant of long-term growth will be the company's execution of its strategy. In 2024, the company appointed a dedicated leader for emerging markets and stated an increased focus on expanding access to its portfolio in the region.
Continue to monitor how the company is addressing emerging markets as a growth opportunity.
As a producer of single-use medical devices, waste and the associated environmental impacts are a key risk for Ambu, particularly given its significant European presence. Failure to manage this could result in future costs to the business and its customers. Equally, having a robust sustainability approach could be a source of competitive advantage.
Ambu consolidated its previously fragmented emerging markets activities into a single global team and exited approximately 40 small, complex countries to focus on 19 priority markets, with India serving as a test bed. This reflects a shift from opportunistic expansion to disciplined execution. Ambu is investing directly in local sales presence, clinician training, and health-economic evidence to support reimbursement and repeat adoption, improving the durability of revenues in emerging markets.